P16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy. [electronic resource]
Producer: 20020614Description: 205-12 p. digitalISSN:- 0167-6806
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Breast Neoplasms -- drug therapy
- Carcinoma, Intraductal, Noninfiltrating -- drug therapy
- Cell Differentiation
- Cyclin-Dependent Kinase Inhibitor p16 -- metabolism
- Cyclophosphamide -- therapeutic use
- Disease-Free Survival
- Female
- Flow Cytometry
- Fluorouracil -- therapeutic use
- Humans
- Immunoenzyme Techniques
- Lymphatic Metastasis
- Methotrexate -- therapeutic use
- Middle Aged
- Neoplasm Staging
- Receptors, Estrogen -- metabolism
- Receptors, Progesterone -- metabolism
- Survival Rate
- Tumor Suppressor Protein p53 -- metabolism
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.